ERNA vs. ATHE, GHSI, GRTX, BFRI, AEZS, GRAY, MTEM, UPC, VIRI, and MBRX
Should you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Alterity Therapeutics (ATHE), Guardion Health Sciences (GHSI), Galera Therapeutics (GRTX), Biofrontera (BFRI), Aeterna Zentaris (AEZS), Graybug Vision (GRAY), Molecular Templates (MTEM), Universe Pharmaceuticals (UPC), Virios Therapeutics (VIRI), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical preparations" industry.
Eterna Therapeutics (NASDAQ:ERNA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
In the previous week, Eterna Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Eterna Therapeutics and 3 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.25 beat Eterna Therapeutics' score of 0.85 indicating that Alterity Therapeutics is being referred to more favorably in the news media.
Alterity Therapeutics' return on equity of 0.00% beat Eterna Therapeutics' return on equity.
Alterity Therapeutics received 3 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.
Alterity Therapeutics has higher revenue and earnings than Eterna Therapeutics.
Alterity Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 248.26%. Given Alterity Therapeutics' higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Eterna Therapeutics.
70.6% of Eterna Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 35.4% of Eterna Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Eterna Therapeutics has a beta of 4.31, meaning that its share price is 331% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.
Summary
Alterity Therapeutics beats Eterna Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Eterna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eterna Therapeutics Competitors List
Related Companies and Tools
